dr. J.F.M. (Job) van Boven

My multidisciplinary research team of physicians, pharmacists, nurses, sociologists, health technologists and health economists aims to optimize real-world drug outcomes and help people and society making more out of our medicines. I have particular interest in personalized and digital medication adherence optimization of drugs used to treat respiratory diseases (asthma, COPD, TB, CF, lung transplantation and lung cancer). 

Research themes include:

(1) Identification of patient groups that could have clinical and/or economic benefit from optimization of adherence

(2) Development, validation and testing of innovative drug-device combinations such as digital inhalers and spacers, electronic pill bottles, injectables and smart blisters that monitor adherence

(3) Assessment of the (cost)effectiveness of (personalized) medication adherence enhancing tools, interventions and strategies using clinical trials.

Current projects:

• MAECON: Medication Adherence Expertise Center Of the northern Netherlands (Founding Director) 
• ENABLE: European Network to Advance Best Practices & Technology on Medication Adherence (ENABLE) - COST Action Network of 40 countries to set up medication adherence expertise centers, review novel technologies, organize short-term fellowships & conferences (Action Chair; STSM student: Katerina Mantila, BPharm; funding: European Commission)
• ACCEPTANCE: Effectiveness and cost-effectiveness of a smart inhaler self-management program to enhance medication adherence in patients with asthma (PhD student: Susanne van de Hei, MD; funding: AstraZeneca)
• On TRACk: Blended intervention on incorporating TRaining, prepAration and Counseling to improve inhaler technique and medication adherence in patients with asthma and/or COPD (PhD student: Roland te Paske, MSc; funding: ZonMw)
• TEVI: Optimising tacrolimus therapy in patients with a lung transplantation by development of electronic drug adherence monitoring tools and assessment of long-term drug exposure in human scalp hair (PhD student: Tanja Zijp, PharmD; funding: Chiesi)
• Prominent: EU Marie Curie Cofund project on cost-effectiveness of personalized medicine (PhD student: Sajad Emamipour, MSc; funding: European Commission)
• OUTER SPACE: Randomised controlled trial to assess the effects of a smart spacer supported educational intervention to enhance medication adherence in patients with asthma and/or COPD (PhD student: Boudewijn Dierick, MD; funding: Trudell Medical)
• Economic evaluations of novel hospital dispensed drugs for lung cancer and ILD (PhD student: Lotte Westerink, PharmD; funding: multisource)
• Pharmaceutical care for patients with TB (PhD student: Deni Iskandar, MPH; funding: Indonesian government-DIKTI scholarship)
• Smart TB pill bottle: Clinical trial to test a smart pill bottle connected with an app to support patients with medication adherence to TB drugs (Post-doc: Samiksha Ghimire, PhD; funding: Pill Connect)
• TAI Toolkit & shared decision making: The impact of shared decision making on asthma/COPD medication adherence and the development of a toolbox with evidence based, personalized adherence interventions following specific responses on the Test of Adherence to Inhalers (TAI) (PhD student: Maria Achterbosch, MSc, RN; funding: Chiesi)
• Care pathway inhalation medication: Implementation assessment of the Dutch National Inhaler Care Pathway/LAN Zorgpad Inhalatiemedicatie (PhD student: Amber Eikholt, MSc; funding: Lung Alliance Netherlands)
• Stronger together: Development of a multidisciplinary patient journey for patients with lung cancer (Project coordinator: Annemieke Visser, PhD; funding: ZonMW)
• AURORA: Adherence and digital inhaler Utilization in a Registry to assess Outcomes in Real-world patients with Asthma (Researchers: Mechteld Wiertz, MD, Amber Eikholt, MSc; funding: Novartis)
• CF Adherence: Enhancing medication adherence to oral cystic fibrosis medication (PhD student: Carina Hansen, PharmD) 

Recently completed projects

• FRESH AIR: Horizon 2020 project focusing on the prevalence, burden and respiratory drug adherence in patients with chronic lung diseases in low and middle income countries Uganda, Kyrgyz Republic, Vietnam and Greece and the implementation of effective interventions (PhD student: Aizhamal Tabyshova, MD; funding: European Commission)
• Real-world data on adverse drug events and medication adherence in economic analyses of respiratory drugs (PhD student: Tanja Fens, PharmD; funding: multisource)

Output from recently completed projects related to respiratory diseases:

2023

• Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial (The Lancet Respiratory Medicine 2023)
• Electronic monitoring devices to support inhalation technique in patients with asthma: A Narrative Review (Current Treatment Options in Allergy 2023)
• Bedaquiline exposure in MDR/XDR-TB patients with diabetes: a sub-analysis of two phase 2 trials (International Journal of Tuberculosis and Lung Disease 2023)
• Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC) (Frontiers in Oncology 2023)

• Clinical and economic burden of drug-susceptible tuberculosis in Indonesia: national trends 2017-19 (The Lancet Global Health 2023)

2022

• Effectiveness, usability and acceptability of a smart inhaler programme in asthma patients: protocol of the multicentre, pragmatic, open-label, cluster randomised controlled ACCEPTANCE trial (BMJ Open Respiratory Research 2022)
• Combining digital adherence technology and therapeutic drug monitoring for personalized TB care (European Respiratory Journal 2022)
• Triple therapy of asthma - permutations and combinations (Journal of Allergy & Clinical Immunology: In Practice 2022)
• Suboptimal peak inspiratory flow and critical inhalation errors are associated with higher COPD-related healthcare costs (International Journal of COPD 2022)
• Towards precision drug therapy in asthma (Annals of Translational Medicine 2022)
• Digital spacer data driven COPD inhaler adherence education: the OUTERSPACE proof-of-concept study (Respiratory Medicine 2022)
• An Inca trail to the holy grail: digital medication adherence support for TB care (International Journal of Tuberculosis and Lung Disease 2022)
• Electronic inhaler monitoring (EIM) for chronic airways disease: Development and application of a Multi-Dimensional Efficacy Framework (Journal of Allergy & Clinical Immunology: In Practice 2022)
• Better use of inhaled medication in asthma and COPD through training, preparation and counseling: the On Track study protocol for a cluster randomised trial (BMJ Open 2022)
• Pharmacology, drug deposition and drug administration techniques of intranasal corticosteroids for treating allergic rhinitis (Clinical & Experimental Allergy 2022)
• Can electronic monitoring with a digital smart spacer support personalized medication adherence and inhaler technique education in patients with asthma?: protocol of the randomized controlled OUTERSPACE trial (BMJ Open 2022)
• Medication availability and economic barriers to adherence in asthma and COPD patients in low-resource settings (npj Primary Care Respiratory Medicine 2022)
• A pharmacy-based eHealth intervention promoting correct use of medication in patients with asthma and COPD: non-randomized pre-post study (Journal of Medical Internet Research 2022)
• Digital Health Technologies to Improve Medication Adherence and Treatment Outcomes in Tuberculosis Patients: A Systematic Review of Randomized Controlled Studies (Journal of Medical Internet Research 2022)
• Improved health status of severe COPD patients after being included in an integrated primary care service: a prospective cohort study (Eur J Gen Pract 2022)
• Digital medication adherence technology: towards personalised TB care (International Journal of Tuberculosis and Lung Disease 2022)
• COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals – EAACI recommendations (Allergy 2022)
• Cost-effectiveness of nintedanib for patients with progressive fibrosing interstitial lung disease (PF-ILD) (Pharmacoeconomics Open 2022)
• Prioritising primary care respiratory research needs: results from the 2020 International Primary Care Respiratory Group (IPCRG) global e-Delphi exercise (npj Primary Care Respiratory Medicine 2022)
• Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma (Journal of Allergy & Clinical Immunology: In Practice 2022)

2021

• When biology meets behaviour: can medication adherence mask the contribution of pharmacogenetic effects in asthma? (European Respiratory Journal 2021)
• Personalizing medication adherence management in asthma and COPD: a review of effective interventions and development of a practical toolkit (Journal of Allergy & Clinical Immunology: In Practice 2021)
• Maximising Adherence and Gaining New Information For Your Chronic Obstructive Pulmonary Disease (MAGNIFY COPD): Study Protocol for the Pragmatic, Cluster Randomised Trial Evaluating the Impact of Dual Bronchodilator with Add-on Sensor and Electronic Monitoring on Clinical Outcomes (Pragmatic and Observational Research 2021)
• Global burden of medication non-adherence in COPD and asthma: a narrative review of the clinical and economic case for smart inhalers (Journal of Thoracic Disease 2021)
• Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade (Journal of Global Health 2021)
• Neuropsychiatric safety of varenicline in the general and COPD population with and without psychiatric disorders: a retrospective cohort study in a real-world setting (BMJ Open 2021)
• Risk of Neuropsychiatric Adverse Events Associated with Varenicline Treatment for Smoking Cessation among Dutch Population: A Sequence Symmetry Analysis (Pharmacoepidemiology & Drug Safety 2021)
• Work absence in patients with asthma/COPD: a population-based study (npj Primary Care Respiratory Medicine 2021)
• Recovery from COVID-19: a sprint or marathon? 6 months follow-up data of online long COVID-19 support group members (ERJ Open 2021)
• GINA 2020: Potential impacts, opportunities and challenges for primary care (Journal of Allergy & Clinical Immunology: In Practice 2021)
• Impact of blood eosinophil variability in asthma: a real-life population study (Annals of the American Thoracic Society 2021)
• Impact of socioeconomic status on adult patients with asthma: a population-based cohort study from UK primary care (Journal of Asthma and Allergy 2021)
• Clinical characteristics, treatment patterns and economic burden of COPD in Kyrgyzstan: a FRESH AIR study (International Journal of Chronic Obstructive Pulmonary Disease 2021)
• Strategies for the Prevention, Diagnosis and Treatment of COPD in Low- and Middle- Income Countries: the Importance of Primary Care (Expert Review of Respiratory Medicine 2021)
• Challenges in the Implementation of COPD Guidelines in Low- and Middle-Income Countries: an ATS Workshop Report (Annals of the American Thoracic Society 2021)
• Gaps in COPD guidelines of low- and middle-income countries: a systematic scoping review (Chest 2021)
• Economic evaluations of Chronic Obstructive Pulmonary Disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse-drug reactions addressed? (Expert Opinion on Pharmacotherapy 2021)

2020

• Trajectories analyses of adherence patterns in a real-life moderate to severe asthma population (Journal of Allergy & Clinical Immunology: In Practice 2020)
• Interventions to improve medication adherence in tuberculosis patients: a systematic review of randomized controlled studies (npj Prim Care Respir Med 2020)
• Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017 (The Lancet Respiratory Medicine 2020)
• Improving adherence to treatment in COPD. A personalised approach (Respiratory Medicine Today 2020)
• Clinical and economic impact of medication non-adherence in drug susceptible tuberculosis: systematic review (International Journal of Tuberculosis and Lung Disease 2020)
• Switching inhalers: a practical approach to keep on UR RADAR (Pulmonary Therapy 2020)
• Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy (Expert Review of Pharmacoeconomics & Outcomes Research 2020)
• Prevalence of Seasonal Influenza Vaccination in Chronic Obstructive Pulmonary Disease (COPD) Patients in the Balearic Islands (Spain) and Its Effect on COPD Exacerbations: A Population-Based Retrospective Cohort Study  (Int J Environ Res Public Health 2020)
• Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper (Clinical and Translational Allergy 2020)
• Home initiation of chronic noninvasive ventilation in COPD patients with chronic hypercapnic respiratory failure: a randomised controlled trial (Thorax 2020)
• Spacers and valved holding chambers-the risk of switching to different chambers (Journal of Allergy & Clinical Immunology: In Practice 2020)
• Prevalence and economic burden of respiratory diseases in Central Asia and Russia: a systematic review (Int J Environ Res Public Health 2020)
• Let's stop dumping cookstoves in local communities: it's time to get implementation right! (npj Primary Care Respiratory Medicine 2020)
• Influence of age of real-life effects of doxycycline for acute exacerbations among COPD outpatients: a population-based cohort study (BMJ Open Respiratory Research 2020)

2019

• Does changing inhaler devices impact real-life asthma outcomes?: Clinical and economic evaluation (Journal of Allergy & Clinical Immunology: In Practice 2019)
• Making sense of cost-effectiveness analysis in respiratory medicine: a practical guide for non-health economists (European Respiratory Journal 2019)
• Costs of case-finding uncovered: time to revisit COPD's value pyramid? (Thorax 2019)
• The socioeconomic burden of chronic lung disease in low-resource settings across the globe- an observational FRESH AIR study (Respiratory Research 2019)
• The hidden story of nonadherence with asthma therapy: for a few dollars more? (Journal of Allergy & Clinical Immunology: In Practice 2019)
• Economic impact of reducing inappropriate inhaled corticosteroids use in patients with COPD: ISPOR's guidance on budget impact in practice (Value in Health 2019)
• Smart medication adherence monitoring in clinical drug trials: a prerequisite for personalised medicine? (EClinicalMedicine 2019)
• Effects and acceptability of implementing improved cookstoves and heaters to reduce household air pollution: a FRESH AIR study (npj Primary Care Respiratory Medicine 2019)
• Prevalence and characteristics of asthma-COPD overlap in routine primary care practices (Annals of the American Thoracic Society 2019)
• Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurised metered dose inhalers in patients with asthma treated with ICS/LABA (Respirology 2019)
• COPD's early origins in low-and-middle-income countries: what are the implications of a false start? (npj Primar Care Respiratory Medicine 2019)
• Development of the International Severe Asthma Registry: a modified Delphi study (Journal of Allergy & Clinical Immunology: In Practice 2019)
• ACO: time to move from the description of different phenotypes to the treatable traits (PLoS One 2019)
• Diabetes mellitus comorbidity in patients enrolled in tuberculosis drug efficacy trials around the world: a systematic review (British Journal of Clinical Pharmacology 2019)
• High COPD prevalence at high altitude: does household air pollution play a role? (European Respiratory Journal 2019)

2018

• The clinical impact of different adherence behaviours in patients with severe COPD (American Journal of Respiratory and Critical Care Medicine 2018)
• Addressing the impact and unmet needs of non-adherence in asthma and COPD: where do we go from here? (Journal of Allergy & Clinical Immunology: In Practice 2018)
• Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations (Pharmacoeconomics 2018)
• Real-life effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK (BMJ Open 2018)
  
• Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients (European Respiratory Journal 2018)
• Personalising adherence enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis (npj Primary Care Respiratory Medicine 2018)
• Asthma cost-effectiveness analyses: are we using the recommended outcomes in estimating value? (Journal of Allergy & Clinical Immunology: In Practice 2018)

2017

• Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 (The Lancet Respiratory Medicine 2017)
• Costly comorbidities of COPD: the ignored side of the coin? (European Respiratory Journal 2017)
• Indacaterol/glycopyrronium is cost-effective compared to salmeterol/flucticasone in COPD: FLAME-based modelling in a Swedish population (Respiratory Research 2017)
• Electric scooters: batteries in the battle against ambient air pollution? (The Lancet Planetary Health 2017)
• In patients with severe uncontrolled asthma, does knowledge of adherence and inhaler technique using electronic monitoring improve clinical decision making?: A protocol for a randomised controlled trial (BMJ Open 2017)
• Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical matched cohort study (Pragmatic & Observational Research 2017)
• Effectiveness and success factors of educational interventions on inhalation technique in asthma & COPD: a systematic review (npj Primary Care Respiratory Medicine 2017)
• Association between chronic comorbidity and exacerbation risk in primary care patients with COPD: a real-life study (Respiratory Research 2017)
• Clinical characteristics, treatment patterns and socio-economic burden of COPD in Bulgaria (Journal of Medical Economics 2017)
• Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic chronic obstructive pulmonary disease maintenance treatments: Methodological challenges and recommendations (Pharmacoeconomics 2017)
• Optimizing identification and management of COPD patients - reviewing the role of the community pharmacist (British Journal of Clinical Pharmacology 2017)
• Urging Europe to put non-adherence to inhaled respiratory medication higher on the policy agenda: a report from the first European Congress on Adherence to Therapy (European Respiratory Journal 2017)

2016

• COPD case finding: effective, but also cost-effective? (The Lancet Respiratory Medicine 2016)
• What we mean when we talk about adherence in respiratory medicine (The Journal of Allergy and Clinical Immunology: In Practice 2016)
• Hollywood raising awareness of smoking-related diseases: can it proactively counteract the impact of smoking in movies? – the final mission of Star Trek’s Mr. Spock (npj Primary Care Respiratory Medicine 2016)
• Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in The Netherlands (International Journal of COPD 2016)
• Enhancing respiratory medication adherence: the role of healthcare professionals and cost-effectiveness considerations (The Journal of Allergy and Clinical Immunology: In Practice 2016)
• Factors associated with the prescription of inhaled corticosteroids in primary care patients with COPD: a cross-sectional study in the Balearic Islands (Spain) (European Journal of General Practice 2016)
• Increasing research capacity and awareness of chronic lung diseases in East Africa (The Lancet Global Health blog 2016)
• Enhancing the use of asthma and COPD assessment tools in Balearic primary care (npj Prim Care Respir Med 2016)
• Investigating the association between medication adherence and health related quality of life in COPD: Methodological challenges when using a proxy measure of adherence (Respir Med 2016)
• Effects of targeted disease and medication management interventions towards patients with COPD (Curr Med Res Opin 2016)
• Higher adherence during reimbursement of pharmacologic smoking cessation treatments (Nicotine & Tobacco Research 2016)
• Comorbidome, pattern and impact of asthma-COPD overlap syndrome (ACOS) in real-life (Chest 2016)

2015

• Predictors of cost-effectiveness of selected COPD treatments in primary care: UNLOCK study protocol (npj Prim Care Respir Med 2015)
• Towards tailored and targeted adherence assessment to optimise asthma management (npj Prim Care Respir Med 2015)
• Mapping the Clinical COPD Questionnaire (CCQ) onto generic preference-based EQ-5D values (Value in Health 2015)

2014

• Clinical and economic impact of non-adherence in patients with COPD: a systematic review (Respiratory Medicine 2014)
• Improving inhaler adherence in patients with Chronic Obstructive Pulmonary Disease: a cost-effectiveness analysis (Respiratory Research 2014)
• Impact of multiple-dose versus single-dose inhaler devices on COPD patients' persistence with long-acting B2-agonists: a dispensing database analysis (NPJ Prim Care Respir Med 2014)

2013

• Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis (Drug Safety 2013)
• COPD in the working age population: The economic impact on both patients and government (COPD 2013)
• Effects of targeted pharmaceutical care in patients with asthma and COPD: results of a pilot study (Pharmaceutisch Weekblad 2013)
• The pharmacists' potential to identify targets for interventions to optimize pharmacotherapy in patients with asthma (Int J Clin Pharm 2013)

Global Burden of Disease

• Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3. (The Lancet 2020)
• Mapping 123 million neonatal, infant and child deaths between 2000 and 2017 (Nature 2019)
• Past, present and future of global health financing: country spending and development assistance for health for 195 countries, 1995-2050 (The Lancet 2019)
• Global Alliance for Chronic Disease researchers' statement on multimorbidity (Lancet Global Health 2018)
• The burden of disease in Greece, health loss, risk factors, and health financing, 2000-16: an analysis of the Global Burden of Disease Study 2016 (The Lancet Public Health 2018)
• Measuring performance on the healthcare access and quality index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease study (The Lancet 2018)
• Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: Findings from the 2015 Global Burden of Disease study
  (Int J Public Health 2018)
• Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016 (The Lancet 2017)
• Measuring progress and projecting attainment of the health related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016 (The Lancet 2017)
• Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (The Lancet 2017)
• Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016 (The Lancet 2017)
• Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (The Lancet 2017)
• Global, regional, and national disability-adjusted life years (DALYs) for 332 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease (GBD) 2016 Study (The Lancet 2017)
• Healthcare access and quality index based on mortality from causes amenable to personal healthcare in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease study 2015 (The Lancet 2017)

Effectiveness and cost-effectiveness of real-world drug optimization in (non-respiratory) chronic diseases

• Half a century of fragmented research on deviations from advised therapies: is this a good time to call for multidisciplinary medication adherence research centres of excellence? (Pharmaceutics 2023)
• Medication adherence measurement methods in registration trials supporting the approval of new medicines in the European Union 2010-2020 (Clinical Pharmacology & Therapeutics 2022)
• Electronic smart blister packages to monitor and support medication adherence: a usability study (Patient Preference & Adherence 2022)
• Swiss priority setting on implementing medication adherence interventions as part of COST Action ENABLE (International Journal of Public Health 2022)
• Adherence to Statin Therapy and Attainment of LDL Cholesterol Targets in an Outpatient Population of Type 2 Diabetes Patients: Analysis in the DIAbetes and LifEstyle Cohort Twente (DIALECT) (Frontiers in Pharmacology 2022)
• Personalizing the use of a intermittently scanned continuous glucose monitoring (isCGM) device in individuals with type 1 diabetes: a cost-effectiveness perspective in the Netherlands (FLARE-NL 9) (J Diabetes Science and Technology 2022)
• Reimbursed medication adherence enhancing interventions in 12 European countries: current state of the art and future challenges (Frontiers in Pharmacology 2022)
• Clinical value of emerging bioanalytical methods for drug measurements: a scoping review of their applicability for medication adherence and therapeutic drug monitoring (Drugs 2021)
• A cross-sectional survey on medication management practices for noncommunicable diseases in Europe during the second wave of the COVID-19 pandemic (Frontiers in Pharmacology 2021)
• Editorial: Digital Tools to Measure and Promote Medication Adherence (Frontiers in Medical Technology 2021)
• European Network to Advance Best practices & technoLogy on medication adherencE (ENABLE): Mission Statement (Frontiers in Pharmacology 2021)
• Effectiveness of a targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: a cluster randomized controlled trial (British Journal of Clinical Pharmacology 2021)
• Process evaluation of implementing a pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesian Community Health Centers (Frontiers in Pharmacology 2021)
• Biochemical Urine Testing of Medication Adherence and its Association with Clinical Markers in an Outpatient Population of Type 2 Diabetes Patients in the DIAbetes and LifEstyle Cohort Twente (DIALECT) study (Diabetes Care 2021)
• Disparities in European healthcare system approaches to maintaining continuity of medication for non-communicable diseases during the COVID-19 outbreak (The Lancet Regional Health - Europe 2021)
• User Acceptability and Technical Robustness Evaluation of a Novel Smart Pill Bottle Prototype Designed to Support Medication Adherence (Patient Preference & Adherence 2020)
• Targeted and tailored pharmacist-led intervention to improve adherence to antihypertensive drugs among patients with type 2 diabetes in Indonesia: study protocol of a cluster randomised controlled trial (BMJ Open 2020)
• Effects, costs and implementation of monitoring kidney transplant patients' tacrolimus level with dried blood spot sampling: a randomised controlled hybrid implementation trial (British Journal of Clinical Pharmacology 2020)
• HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups (Diabetes, Obesity and Metabolism 2018)
• Availability, use and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji (BMC Health Serv Res 2018)
• Economic evaluations of pharmacogenetic and pharmacogenomic screening tests: a systematic review. Second update of the literature. (PLoS One 2016)
• Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication (Osteoporosis International 2014)
• Improving adherence to lipid-lowering therapy in a community pharmacy intervention program: a cost-effectiveness analysis (J Manag Care Pharm 2014)
• Medication Monitoring and Optimization (MeMO): a targeted pharmacists’ program for effective and cost-effective improvement of chronic therapy adherence (J Manag Care Pharm 2014) 
• Economic Evaluation of Ropinirole Prolonged-Release for Treatment of Parkinson’s Disease in The Netherlands (Drugs Aging 2014)
• Persistence with osteoporosis medication among newly-treated osteoporotic patients (J Bone Miner Metab 2013)
• Proactive pharmaceutical care interventions improve patients' adherence to lipid-lowering medication (Annals Pharmacotherapy 2013)
• Cost-effectiveness of improving adherence to bisphosphonates therapy in patients with osteoporosis (Pharmaceutisch Weekblad 2011)